Lasofoxifene in Postmenopausal Women with Osteoporosis
Steven R. Cummings(University of California, San Francisco), Richard Eastell(University of Sheffield), José Zanchetta(Universidad del Salvador), Slobodan Vukičević(University of Zagreb), Kristine E. Ensrud(University of Minnesota), Steven R. Goldstein(New York University), Andrea Z. LaCroix(Human Longevity (United States)), John R. Thompson(University of Leicester), Andy Lee(Pfizer (United States)), Pierre D. Delmas(Inserm), David D. Thompson(Pfizer (United States)), Usha Sriram, Trevor J. Powles(Royal Marsden NHS Foundation Trust), David M. Reid(University of Aberdeen), Patrick Neven(KU Leuven), Róisín Armstrong(Pfizer (United States)), David L. Kendler(University of British Columbia)
Cited by 388
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
A framework for the investigation of pleiotropy in two‐sample summary data Mendelian randomization
|Statistics in Medicine|2017|2k
Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome
|Statistics in Medicine|2015|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k